APA (7th ed.) Citation

P, M., MP, Y., SA, P., SE, P., D, G., A, P., & AD, A. (2024). The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 35(2), 365. https://doi.org/10.1007/s00198-023-06931-3

Chicago Style (17th ed.) Citation

P, Makras, Yavropoulou MP, Polyzos SA, Papapoulos SE, Georgakopoulou D, Papatheodorou A, and Anastasilakis AD. "The Relationship Between Length of Denosumab Treatment for Postmenopausal Osteoporosis and Serum TRAcP5b Measured Six Months After the Last Injection." Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 35, no. 2 (2024): 365. https://doi.org/10.1007/s00198-023-06931-3.

MLA (9th ed.) Citation

P, Makras, et al. "The Relationship Between Length of Denosumab Treatment for Postmenopausal Osteoporosis and Serum TRAcP5b Measured Six Months After the Last Injection." Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 35, no. 2, 2024, p. 365, https://doi.org/10.1007/s00198-023-06931-3.